Novartis Ag (NVS) Net Income towards Common Stockholders Growth (3y) (2012 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
76.51% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
131.31% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
109.43% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-51.68% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-13.81% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
27.11% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-146.62% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
5.72% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
-3.80% |
| Dec 31, 2024 |
5.38% |
| Jun 30, 2024 |
-13.74% |
| Dec 31, 2023 |
-66.17% |
| Sep 30, 2023 |
-25.48% |
| Jun 30, 2023 |
-79.82% |
| Mar 31, 2023 |
-9.46% |
| Mar 31, 2022 |
99.09% |
| Dec 31, 2021 |
513.65% |
| Sep 30, 2021 |
64.95% |
| Jun 30, 2021 |
430.89% |
| Mar 31, 2021 |
106.94% |
| Dec 31, 2020 |
112.30% |
| Sep 30, 2020 |
0.96% |
| Jun 30, 2020 |
34.24% |
| Mar 31, 2020 |
-28.15% |
| Mar 31, 2019 |
-36.55% |
| Dec 31, 2018 |
-146.62% |
| Sep 30, 2018 |
-72.22% |
| Jun 30, 2018 |
12,949.56% |
| Mar 31, 2018 |
4,716.74% |
| Dec 31, 2017 |
8,012.07% |
| Sep 30, 2017 |
16,102.66% |
| Jun 30, 2017 |
25,499.06% |
| Mar 31, 2017 |
9,958.03% |
| Sep 30, 2016 |
17,032.27% |
| Jun 30, 2016 |
24,205.68% |
| Sep 30, 2015 |
5,263.30% |
| Jun 30, 2015 |
-26.62% |
| Mar 31, 2015 |
-0.51% |
| Dec 31, 2014 |
-43.61% |
| Sep 30, 2014 |
-36.50% |
| Jun 30, 2014 |
-30.96% |
| Mar 31, 2014 |
-10.33% |
| Sep 30, 2013 |
-44.61% |
| Jun 30, 2013 |
-27.71% |
| Sep 30, 2012 |
733.23% |
| Jun 30, 2012 |
774.55% |
| Mar 31, 2012 |
746.12% |
